A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335, Odalasvir, and Simeprevir

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2015
The purpose of this study is to evaluate the safety and tolerability of AL-335 in combination with odalasvir (ODV) with or without simeprevir (SMV) in participants with genotype (GT)1 or GT2 or GT3 chronic hepatitis C (CHC) infection.
Epistemonikos ID: 38deb19a5cb81014d5543ed1d3bb469d28decee3
First added on: May 12, 2024